How Novohope's Oral Dissolvable Films Are Reshaping Pet Supplement Delivery

The pet health supplement industry is undergoing a quiet revolution in formulation science. While traditional tablets, powders, and chews remain dominant, a new delivery mechanism is gaining traction: the orally disintegrating film (ODF). Among the early movers in this space is Novohope, a brand built around the concept of flash-release films that promise rapid absorption and stress-free administration. This article examines how Novohope's approach addresses long-standing pain points in pet supplementation, and what it means for retailers, distributors, and pet owners seeking measurable results.

The Problem: Why Traditional Pet Supplements Fall Short

Giving a pet a daily supplement often becomes a battle of wills. Tablets are hidden in food and then spit out; powders get mixed unevenly; chews may be refused by picky eaters. Beyond palatability, there is a deeper biological issue: a pet's digestive system is not ideal for oral nutrient absorption. The canine or feline gut is short (less than 1.2 metres) and highly acidic (pH 1–3), which degrades many active ingredients before they can be utilised. Estimates suggest that conventional oral products achieve an absorption rate of only about 35%. For pet owners investing in premium nutrients, that inefficiency means a significant portion of each dose is wasted.

The Opportunity: A Delivery Platform Built for Pet Physiology

Novohope (Wuxi Novohope Biotechnology Co., Ltd.) was established in 2025 with a specific focus on applying orally disintegrating film technology to pet health. The company operates a 20,000 m² facility in Wuxi, Jiangsu, with an annual production capacity of 200 million boxes and an R&D team of 12 engineers. Its core offering is a portfolio of seven product series — COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO, and Fit+ — each formulated as a thin, postage-stamp-sized film or tablet that dissolves in the pet's mouth within seconds.

Technical Explanation: How the Oral Dissolving Film Works

The mechanism is rooted in established human pharmaceutical technology. An ODF is a solid film matrix loaded with active ingredients. When placed on the tongue or inner cheek, saliva triggers rapid disintegration — Novohope's films dissolve in under 10 seconds. The resulting slurry of bioactives is absorbed directly through the oral mucosa, which is rich in blood vessels. This bypasses the gastrointestinal tract entirely, avoiding degradation by stomach acid and enzymes. Novohope claims an absorption rate of up to 95% via this route, a substantial improvement over the ~35% of traditional oral supplements.

Key ingredients per film vary by variant. For instance, the EYES+ film (2.1 g) contains eye care nutrients such as Lutein and Zeaxanthin to help manage tear stains and support vision. The PROBIO film (2.5 g) delivers 1×10⁹ CFU of Bacillus coagulans (GBI-30, 6086) along with postbiotics. All products have completed FDA food registration, obtained GS1 international product codes, and passed SDS and COA testing, establishing a global compliance framework.

Application Scenarios: Targeted Health Solutions for Everyday Needs

Novohope's seven series are designed for common pet wellness goals. The table below summarises the functional focus and applicable use cases for each model in the portfolio.

These products find natural application in retail, online sales, and veterinary channels. The films are individually packed, making them portable and easy to administer without mess or measurement.

Market Trend Analysis

The global pet supplements market was valued at approximately USD 2.8 billion in 2025, with projections reaching USD 4.6 billion by 2033, according to Grand View Research. North America currently accounts for 48.1% of global revenue, while Asia-Pacific is emerging as the fastest-growing region due to rising pet humanisation and healthcare expenditure. Within this landscape, innovative delivery formats are gaining attention. The oral dissolving film sector in veterinary nutrition is nascent but growing, with industry reports indicating a focus on disintegration times below 25 seconds and palatability improvements of up to 47%.

Novohope's positioning — combining biomedical R&D (its technical team originates from the Wahsheer Biotechnology Laboratory at the Chinese University of Hong Kong) with a full compliance stack — allows it to serve both the high-volume retail market and specialised ODM/OEM clients across Europe, America, Britain, the Middle East, Japan, and South Korea. Approximately 95% of its production is exported.

Comparison with Traditional Solutions

When placed side by side with conventional tablets, powders, and chews, Novohope's oral films offer measurable advantages in absorption efficiency, dosing accuracy, and ease of feeding. However, the format is relatively new to pet owners — many are accustomed to familiar shapes and flavours. One honest limitation is that the film format requires the pet to be willing to accept a novel texture, although palatability has been engineered for high acceptance. Additionally, while the ODF technology dramatically boosts absorption, it does not replace veterinary-prescribed medications for diagnosed conditions; it is a nutritional supplement, not a drug.

Future Outlook

As pet parents increasingly seek results and convenience, delivery platforms that maximise bioavailability will likely gain share. Novohope's investment in ODF technology positions it well for the next phase of the market, where efficacy and user experience become core differentiators. The company's recent participation at Interzoo 2026 (Nuremberg) and its selection for the Wuxi Taihu Cup Innovation Competition underscore growing industry recognition.

Frequently Asked Questions